Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL

CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to tisagenlecleucel. However, several questions remain unresolved.

Automated summary

CAR T-cell therapy has revolutionized the treatment of relapsed/refractory DLBCL, but the availability of multiple products has raised questions about treatment selection and balancing toxicity with efficacy.